Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 7/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | PPOX | P50336 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22687457 | 0.84 | TDP1 (0.55) | ERN1TDP1PTPN1HSD17B10XDH | |
| SCHEMBL584206 | 0.80 | ERN1 (0.52) | ERN1TDP1PTPN1HSD17B10HPGD | |
| SCHEMBL22654821 | 0.78 | CA12 (0.32) | ERN1TDP1MEN1KMT2A | |
| SCHEMBL15428103 | 0.76 | SRC (0.43) | ERN1TDP1HPGDTSHRALDH1A1 | |
| SCHEMBL15428101 | 0.76 | ALDH1A1 (0.39) | ERN1TDP1PTPN1ALDH1A1KDM4E | |
| SCHEMBL4357334 | 0.73 | TDP1 (0.70) | ERN1TDP1PTPN1HSD17B10XDH | |
| Chlorobenzene SCHEMBL28196887 | 0.73 | KMT2A (0.43) | ERN1TDP1HSD17B10HPGDTSHR | |
| SCHEMBL28537631 | 0.73 | PTGDR2 (0.47) | ERN1TDP1HSD17B10HPGDALDH1A1 | |
| SCHEMBL22685386 | 0.72 | ERN1 (0.56) | ERN1TDP1TSHRALDH1A1KDM4E | |
| SCHEMBL22687434 | 0.72 | ALOX5AP (0.36) | ERN1PTPN1HSD17B10HPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10913770-B2 | Mertansine polypeptide conjugates | VISION GLOBAL HOLDINGS LIMITED (CN) | 2021-02-09 | — | — | US | disclosed |
| US-20200361988-A1 | MERTANSINE POLYPEPTIDE CONJUGATES | VISION GLOBAL HOLDINGS LIMITED (HK) | 2020-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361988-A1 | MERTANSINE POLYPEPTIDE CONJUGATES | NGLY1, ANPEP, VIP | ERN1 4075/4885TDP1 3450/4885PTPN1 2608/4885 |
| US-10913770-B2 | Mertansine polypeptide conjugates | NGLY1, ANPEP, VIP | ERN1 4075/4885TDP1 3450/4885PTPN1 2608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.